165 related articles for article (PubMed ID: 35955791)
1. Cellular Metabolism and Bioenergetic Function in Human Fibroblasts and Preadipocytes of Type 2 Familial Partial Lipodystrophy.
Algieri C; Bernardini C; Trombetti F; Schena E; Zannoni A; Forni M; Nesci S
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955791
[TBL] [Abstract][Full Text] [Related]
2. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction.
Schena E; Mattioli E; Peres C; Zanotti L; Morselli P; Iozzo P; Guzzardi MA; Bernardini C; Forni M; Nesci S; Caprio M; Cecchetti C; Pagotto U; Gabusi E; Cattini L; Lisignoli G; Blalock W; Gambineri A; Lattanzi G
Cells; 2023 Nov; 12(22):. PubMed ID: 37998321
[TBL] [Abstract][Full Text] [Related]
4. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
Friesen M; Cowan CA
Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
[TBL] [Abstract][Full Text] [Related]
5. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
Corsa CAS; Walsh CM; Bagchi DP; Foss Freitas MC; Li Z; Hardij J; Granger K; Mori H; Schill RL; Lewis KT; Maung JN; Azaria RD; Rothberg AE; Oral EA; MacDougald OA
Diabetes; 2021 Sep; 70(9):1970-1984. PubMed ID: 34088712
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
[TBL] [Abstract][Full Text] [Related]
8. Itm2a silencing rescues lamin A mediated inhibition of 3T3-L1 adipocyte differentiation.
Davies SJ; Ryan J; O'Connor PBF; Kenny E; Morris D; Baranov PV; O'Connor R; McCarthy TV
Adipocyte; 2017 Oct; 6(4):259-276. PubMed ID: 28872940
[TBL] [Abstract][Full Text] [Related]
9. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning.
Pellegrini C; Columbaro M; Schena E; Prencipe S; Andrenacci D; Iozzo P; Angela Guzzardi M; Capanni C; Mattioli E; Loi M; Araujo-Vilar D; Squarzoni S; Cinti S; Morselli P; Giorgetti A; Zanotti L; Gambineri A; Lattanzi G
Exp Mol Med; 2019 Aug; 51(8):1-17. PubMed ID: 31375660
[TBL] [Abstract][Full Text] [Related]
10. Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.
Le Dour C; Wu W; Béréziat V; Capeau J; Vigouroux C; Worman HJ
J Lipid Res; 2017 Jan; 58(1):151-163. PubMed ID: 27845687
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
[TBL] [Abstract][Full Text] [Related]
13. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
[TBL] [Abstract][Full Text] [Related]
14. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
[TBL] [Abstract][Full Text] [Related]
15. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
Gambineri A; Zanotti L
Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
[TBL] [Abstract][Full Text] [Related]
17. Generation of an isogenic gene-corrected iPSC line (PUMCHi001-A-1) from a familial partial lipodystrophy type 2 (FPLD2) patient with a heterozygous R349W mutation in the LMNA gene.
Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
Stem Cell Res; 2020 Apr; 44():101753. PubMed ID: 32213461
[TBL] [Abstract][Full Text] [Related]
18. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Dietary Intake, Leisure-Time Physical Activity, and Metabolic Profile in Women with Mutation in the LMNA Gene.
Monteiro L; Foss-Freitas MC; Navarro A; Pereira F; Coeli F; Carneseca E; Júnior RM; Foss M
J Am Coll Nutr; 2017; 36(4):248-252. PubMed ID: 28443701
[TBL] [Abstract][Full Text] [Related]
20. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
